Drug Safety
My favorite three presentations from day 4 at ACR 2021 included the following:
Breakthrough Infections in Rheumatic Disease Patients
Late-Breaking Abstract L16 - Dr. Jazvinder Singh presented the…
3 years 1 month ago
Retrospective chart review of rheumatic irAE patients:
Persistent rheumatic irAE activity 🔼received GC
Inflammatory arthritis pts 🔼risk of persistent rheumatic irAE
Risk factors for mortality➡️tumor progression➕ continued Rx GC at last follow-up
Abst#1516 #ACR21 @RheumNow https://t.co/KusNaVlEXp
3 years 1 month ago
Abst 1517
Weinmann & colleagues studied prevalence of autoantibodies in Melanoma pts treated w/ ICI & developed rheumatic IRAE
- Most common rheumatic IRAE = inflammatory arthritis
- Higher prevalence of ANA in those tx w/ chemo prior to ICI
#ACR21 @RheumNow https://t.co/7qgogSMjUr
Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites:
Secukinumab Efficacy in Enthesitis-Related and Juvenile Psoriatic Arthritis.
Abstract 1424 – Dr. Hermine…
Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions?
The NOR-DRUM trials (A and B) are the first randomized trials to assess…